Reaction times (approach bias)
Time frame · Baseline and after treatment (2-4 months)
Changes in reaction times (approach bias) in response to pictures of high-calorie and low-calorie foods after treatment.
Status
Recruiting
Phase
Not applicable
Enrollment
50
Locations
1
Results
Not posted
Publications
0
Study summary
The present research project aims to study the effects of bariatric surgery and liraglutide administration (in patients already selected for one of these procedures) on two cognitive-behavioral processes partially supported by distinct brain networks: automatic approach tendencies (underpinned by the cue-reactivity network) and behavioral inhibition (underpinned by the cue-regulation network). Additionally, the investigators aim to study how these processes may be modulated by satiety. The secondary objective of the project includes identifying cognitive-behavioral markers that can predict the response to these treatments.
Experimental and meta-analytic neuroimaging studies have highlighted two primary brain networks whose functioning or structure is altered in patients with obesity: (i) the "cue-reactivity network," involved in sensory, hedonic, and motivational responses to food, and (ii) the "cue-regulation network," more prominently involved in attentional, decision-making, and inhibitory processes. In line with this theoretical framework, weight loss induced by pharmacological treatments or bariatric surgery is associated with a partial recovery of the functioning and structure of these brain networks. Following a sleeve gastrectomy, obese patients exhibit reduced activity in the reward circuit and increased activity in the inhibitory control circuit in response to high-calorie food images, suggesting a normalization of brain responses to food after bariatric surgery. Moreover, these changes in brain functionality may be accompanied by increased gray matter density in the prefrontal cortex, which persists for up to 12 months following sleeve gastrectomy or Roux-en-Y gastric bypass. Pharmacologically, the administration of glucagon-like peptide-1 receptor (GLP-1) agonists-such as liraglutide, semaglutide, and exenatide-has proven effective in treating diabetes and promoting weight loss. fMRI studies have shown that intravenous administration of exenatide (vs. placebo) in patients with obesity and type 2 diabetes reduces neurofunctional activity in key nodes of the cue-reactivity network (e.g., amygdala, putamen, insula) in response to high-calorie food images. Furthermore, this effect is nullified if exenatide administration is preceded by GLP-1 receptor blockade. However, it remains unclear whether such surgical or pharmacological treatments are accompanied by changes in cognitive processes associated with reactivity to edible stimuli or behavioral inhibition, and whether these contribute to an improved post-operative response to satiety. This research project thus aims to study the effects of bariatric surgery and liraglutide administration (in patients already selected for one of these procedures) on two cognitive-behavioral processes partially supported by distinct brain networks: automatic approach tendencies (underpinned by the cue-reactivity network) and behavioral inhibition (underpinned by the cue-regulation network). Additionally, the investigators aim to study how these processes may be modulated by satiety. The secondary objective of the project involves identifying cognitive-behavioral markers that could predict responses to these treatments.
Interventions
No intervention details reported.
Timeline
First posted
Dec 6, 2024
Study start
Jun 26, 2024
Primary completion
May 1, 2027
Study completion
May 1, 2027
Results posted
Not reported
Registry updated
Dec 11, 2024
Outcomes
Reaction times (approach bias)
Time frame · Baseline and after treatment (2-4 months)
Changes in reaction times (approach bias) in response to pictures of high-calorie and low-calorie foods after treatment.
Accuracy (inhibition)
Time frame · Baseline and after treatment (2-4 months)
Changes in accuracy (inhibition) in response to high-calorie and low-calorie food pictures after treatment.
Not reported in the indexed record.
Eligibility
Inclusion Criteria: * Subjects of any ethnicity, aged between 20 and 60 years. * BMI equal to or greater than 30 kg/m². * No history of neurological or psychiatric disorders, as confirmed through medical history and neuropsychological screening. * Signed informed consent and willingness to comply with all study procedures. * Patients scheduled for surgery, treatment with liraglutide, or a dietary regimen. Exclusion Criteria: * Previous diagnosis of significant neurological conditions (e.g., brain injury or dementia) or major psychiatric disorders. * Current or past psychopharmacological therapy, if prolonged. * BMI lower than 30 kg/m². * Lack of signed informed consent. * Severe medical conditions, including but not limited to: hypertension, significant cardiac disease, or other disorders that may compromise patient safety. * Confirmed pregnancy through self-report and/or breastfeeding.
Study locations
Italy. Showing up to 24 locations stored in the fast local snapshot.
IRCCS Ospedale Galeazzi-Sant'Ambrogio
Milan, Milan, Italy
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
The Cleveland Clinic · Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) · Non-Alcoholic Fatty Liver Disease
Phase 4
Recruiting
120
2026-07
4Moving Biotech · Knee Osteoarthritis · Synovitis of Knee
Phase 2
Active, not recruiting
129
2026-07
Ohio State University · Obesity & Overweight · Diabetes (DM)
Not applicable
Recruiting
300
2026-07
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Type 2 Diabetes Mellitus · Mild Cognitive Impairment
Not applicable
Completed
396
2026-07
Phase 1
Recruiting
71
2026-07
Novo Nordisk · Obesity
Phase 3
Active, not recruiting
78
2026-07
West China Hospital · Alzheimer Disease · Diabetes Mellitus Type 2
Not applicable
Completed
213,891
2026-07
Indiana University · Obesity
Not applicable
Enrolling by invitation
125,000
2026-06
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.